Guardant Health Inc. Common Stock (GH)
Stock · NASDAQ · Health Care
$158.63as of 10/16/2026
Price chart
Active signals
GH Signal Track Record
How signals performed across all stocks →What GH's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 30 | +2.1% | 53% | September 18, 2026 |
| Bollinger Band Breakout | 25 | +8.6% | 60% | September 15, 2026 |
| Bollinger Band BreakdownActive now | 20 | +9.1% | 60% | April 10, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -10.8% | 38% | April 28, 2026 |
| Any 20-session window (baseline) | +1.5% | 54% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About GH
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect can…
- Sector
- Health Care
- Industry
- Medical Specialities
- Employees
- 2,490
- Website
- guardanthealth.com/
Fundamentals
- 1-day range
- $159$168.86
- Market cap
- $21.15B
- P/E (trailing)
- —
- P/E (forward)
- -405.92
- EPS (trailing)
- $-3.50
- Dividend yield
- —
- Beta
- 1.70
- Avg. volume
- 1.95M
How Guardant Health Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 19, 2026 · via SEC EDGAR / Finnhub
Forecasts
25 analyst ratings
Guardant Health Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- GHGuardant Health Inc. Common Stock$158.6▼ 4.39%Market cap $21.15BP/E —$61$191.05
- LHLabcorp Holdings Inc. Common Stock$317.95▼ 2.19%Market cap $25.96BP/E 25.55$244.52$341.8
- DGXQuest Diagnostics Incorporated Common Stock$235▼ 1.74%Market cap $26.32BP/E 24.67$171.18$248.84
- ILMNIllumina Inc. Common Stock$262.54▼ 2.01%Market cap $29.25BP/E 48.62$88$309.35
- CNCCentene Corporation Common Stock$69.16▼ 1.91%Market cap $31.71BP/E —$31.63$70.37
- MOHMolina Healthcare Inc Common Stock$207.36▼ 2.42%Market cap $10.02BP/E 1257.31$121.06$244.89
- OSCROscar Health Inc. Class A Common Stock$31.89▼ 4.72%Market cap $8.00BP/E 18.32$10.69$35.01
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| GH Guardant Health Inc. Common Stock | $21.15B | — | $158.6 | ▼ 4.39% | $61$191.05 |
| LH Labcorp Holdings Inc. Common Stock | $25.96B | 25.55 | $317.95 | ▼ 2.19% | $244.52$341.8 |
| DGX Quest Diagnostics Incorporated Common Stock | $26.32B | 24.67 | $235 | ▼ 1.74% | $171.18$248.84 |
| ILMN Illumina Inc. Common Stock | $29.25B | 48.62 | $262.54 | ▼ 2.01% | $88$309.35 |
| CNC Centene Corporation Common Stock | $31.71B | — | $69.16 | ▼ 1.91% | $31.63$70.37 |
| MOH Molina Healthcare Inc Common Stock | $10.02B | 1257.31 | $207.36 | ▼ 2.42% | $121.06$244.89 |
| OSCR Oscar Health Inc. Class A Common Stock | $8.00B | 18.32 | $31.89 | ▼ 4.72% | $10.69$35.01 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- TwinStrand Biosciences Announces U.S. Patent And Trademark Office's Patent Trial And Appeal Board Rejects Guardant Health's Challenge To Core Patent Underlying Duplex Sequencingbenzinga · 10/15/2026
- Grail (GRAL) vs Guardant Health (GH): Which is a Better Stock to Buy?Yahoo · 10/9/2026
- Could You Have Seen The Run In Tempus AI Stock Coming?Yahoo · 10/9/2026
- Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast CancerYahoo · 10/8/2026
- Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026Yahoo · 10/8/2026
- Guardant Health Receives European Approval Of Guardant360 CDx As Companion Diagnostic For AstraZeneca’s ETCAMAHBenzinga · 10/8/2026
- Liquid Biopsy Market to Reach US$15.1 Billion by 2030 at 13.2% CAGR, Driven by Early Cancer Detection and Precision MedicineYahoo · 10/8/2026
- Natera: Priced To Perfection Amidst Rising Competitive ThreatsSeekingAlpha · 10/7/2026
- Dow Jones Futures Fall, Yields Rise After S&P 500 Hits High; Astera, GE Vernova, Arista Lead BuysYahoo · 10/7/2026
Insider Activity
Insider Actions →- Chris Freeman · October 1, 2026 · Option Exercise1.3K
- Chris Freeman · October 1, 2026 · Option Exercise2.5K
- Chris Freeman · October 1, 2026 · Option Exercise1.7K
- Chris Freeman · October 1, 2026 · Option Exercise1.9K
- AmirAli Talasaz · October 1, 2026 · Tax Withholding17.1K @ $174.75
- Helmy Eltoukhy · October 1, 2026 · Option Exercise9.7K
- Terilyn J. Monroe · October 1, 2026 · Option Exercise1.4K
- Terilyn J. Monroe · October 1, 2026 · Option Exercise2.7K
- Terilyn J. Monroe · October 1, 2026 · Tax Withholding2.1K @ $174.75
- Darya Chudova · October 1, 2026 · Option Exercise1.7K
- Darya Chudova · October 1, 2026 · Option Exercise3.3K
- Darya Chudova · October 1, 2026 · Option Exercise1.7K
- Darya Chudova · October 1, 2026 · Option Exercise1.3K
- Darya Chudova · October 1, 2026 · Tax Withholding4.3K @ $174.75
- Kumud Kalia · October 1, 2026 · Option Exercise1.4K
Institutional Ownership
March 31, 2026
- Total shares held
- 131.88M
- Total value held
- $11.05B
- Institutional holders
- 478
- Unknown11.55M
- Unknown7.02M
- Unknown5.62M
- Unknown4.95M
- Unknown4.44M
- Unknown4.23M
- Unknown4.12M
- Unknown3.86M
- Unknown3.51M
- Unknown3.48M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Guardant Health Wins Patent Ruling, Morgan Stanley Lifts Target
Guardant Health secured a favorable decision from the U.S. Patent Trial and Appeal Board, which rejected a challenge to its core duplex sequencing patent. This legal win supports the company's position in the growing liquid biopsy market. Additionally, Morgan Stanley maintained an Overweight rating and raised its price target to $200, citing strong fundamentals in the diagnostics sector.
Guardant Health Wins Patent Ruling, Morgan Stanley Lifts Target. Guardant Health secured a favorable decision from the U.S. Patent Trial and Appeal Board, which rejected a challenge to its core duplex sequencing patent. This legal win supports the company's position in the growing liquid biopsy market. Additionally, Morgan Stanley maintained an Overweight rating and raised its price target to $200, citing strong fundamentals in the diagnostics sector.